NCT05327894 2026-04-13
Interfant-21
Princess Maxima Center for Pediatric Oncology
Phase 3 Recruiting
Clinical Trials
153 trialsNCT01503632 2026-04-08
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Children's Oncology Group
Phase 3 Completed
NCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT01190930 2026-03-31
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT04307576 2026-03-27
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase 3 Recruiting
NCT03844048 2026-03-20
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting
NCT02845882 2026-03-18
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China
Phase 3 Active not recruiting
NCT05602194 2026-03-12
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group
Phase 3 Recruiting
NCT05316701 2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3 Active not recruiting
NCT07223190 2026-03-04
AUDAX
Amgen
Phase 3 Not yet recruiting
NCT02730299 2026-02-25
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
Phase 3 Completed
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT00400946 2026-02-13
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Phase 3 Completed
NCT03020030 2026-01-22
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT05457556 2025-12-22
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group
Phase 3 Active not recruiting
NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT02003222 2025-11-28
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07203352 2025-10-02
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Nanfang Hospital, Southern Medical University
Phase 3 Recruiting
NCT02716233 2025-09-16
CAALL-F01
Assistance Publique - Hôpitaux de Paris
Phase 3 Active not recruiting
NCT07152041 2025-09-03
CAMS-Ph+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Recruiting
NCT03643276 2025-04-06
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
University Hospital Schleswig-Holstein
Phase 3 Recruiting
NCT04043494 2025-03-21
LBL 2018
University Hospital Muenster
Phase 3 Recruiting
NCT04314219 2025-03-13
PTCy-PMAT
King Faisal Specialist Hospital & Research Center
Phase 3 Recruiting
NCT04722848 2025-01-23
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Active not recruiting
NCT00557193 2024-07-15
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT05029531 2024-06-28
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT02393859 2024-05-29
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Completed
NCT06179732 2024-04-23
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities
The Mentor Initiative
Phase 3 Completed
NCT00381680 2024-03-26
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT02013167 2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Terminated
NCT05663827 2024-03-05
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Chang Gung Memorial Hospital
Phase 3 Completed
NCT01802814 2024-02-09
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
Phase 3 Completed
NCT05515029 2023-09-28
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Active not recruiting
NCT01951885 2023-09-11
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center
Phase 3 Completed
NCT00199043 2023-03-17
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Goethe University
Phase 3 Completed
NCT03476239 2023-02-08
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Completed
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT00406393 2023-01-04
BMT CTN 0402
Medical College of Wisconsin
Phase 3 Completed
NCT00549848 2022-08-23
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT02999854 2022-05-24
HATCY
Kiadis Pharma
Phase 3 Terminated
NCT00450450 2022-04-28
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
Children's Oncology Group
Phase 3 Completed
NCT02670252 2022-04-08
BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 3 Completed
NCT02566395 2022-04-07
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Northwell Health
Phase 3 Completed
NCT04375683 2022-03-24
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Zhongda Hospital
Phase 3 Unknown
NCT02369653 2022-03-08
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Bristol-Myers Squibb
Phase 3 Completed
NCT05233683 2022-02-10
Caudal Block Versus Dorsal Penile Nerve Block Plus Ring Block for Pain Management of Different Surgical Techniques of Circumcision in Infants and Children
King Saud University
Phase 3 Unknown
NCT01597778 2021-12-01
Double Cord Versus Haploidentical (BMT CTN 1101)
Medical College of Wisconsin
Phase 3 Completed
NCT00412360 2021-10-28
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
Medical College of Wisconsin
Phase 3 Completed
NCT01439347 2021-09-09
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00651261 2021-08-18
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Unknown